Amgen Successfully Completes Acquisition of ChemoCentryx
Blog TAVNEOS® (avacopan), a First-in-Class Medicine for Patients With Severe Active ANCA-Associated Vasculitis, Added to Inflammation Portfolio THOUSAND OAKS, Calif., (Oct. 20, 2022) – Amgen (NASDAQ: AMGN) today announced that it has successfully completed its previously announced acquisition of ChemoCentryx, Inc. (NASDAQ: CCXI), a biopharmaceutical company focused on orally administered therapeutics to treat autoimmune diseases, inflammatory disorders […]
US FDA approves Regeneron-Sanofi’s Kevzara to treat polymyalgia rheumatica
Blog The US Food and Drug Administration (FDA) has granted approval for Regeneron Pharmaceuticals and Sanofi’s Kevzara (sarilumab) to treat polymyalgia rheumatica (PMR) in adult patients. Kevzara has been approved as the first and only biologic indicated for PMR adult patients who did not respond to corticosteroids or who cannot tolerate corticosteroid taper. Developed using […]
New Kawasaki Disease Guideline Released by American College of Rheumatology and Vasculitis Foundation
Blog Newswise — ATLANTA — The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released a new guideline for the management of Kawasaki disease that addresses diagnostic issues relating to Kawasaki disease, the treatment of high-risk patients, and the management of convalescent patients. Kawasaki disease is a vasculitis that is most […]
The American College of Rheumatology/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis
Blog FOR IMMEDIATE RELEASE July 9, 2021 Media Contact Amanda Head (Corna) acorna@rheumatology.org 404-679-5330 The American College of Rheumatology/Vasculitis Foundation Release Three New Guidelines for Treatment of Vasculitis ATLANTA — The American College of Rheumatology (ACR), in partnership with the Vasculitis Foundation (VF), released three new guidelines for the treatment and management of systemic vasculitis. Vasculitis is a group of about 20 rare diseases […]
ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis
Blog ChemoCentryx Announces Filing of Amendment to NDA Submission and Extension of the PDUFA Review Period for Avacopan in the Treatment of ANCA-Associated Vasculitis SAN CARLOS, Calif., July 06, 2021 (GLOBE NEWSWIRE) — ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that, following consultations with the U.S. Food and Drug Administration (FDA), it filed an amendment to […]